

# Do you or a loved one experience frequent HAE attacks?

Learn more about Oasis, a clinical research study for people with hereditary angioedema (HAE).

## What is the Oasis study?

The Oasis study is a clinical research study evaluating the safety and effectiveness of donidalorsen, an investigational study drug for HAE. The Oasis study is being conducted to help address the need for new therapies for HAE.

## What is the study drug?

The study drug is called donidalorsen (don-id-a-lor-sen). Donidalorsen is designed to lower the amount of a protein called prekallikrein (PKK) in the body. By lowering PKK, donidalorsen may help reduce or prevent HAE attacks.

Donidalorsen is an injection that is administered under the skin of the upper arm, abdomen, or thigh.

## Who can join the Oasis study?

You may qualify for the study if you meet the following requirements:

- You are 12 years of age or older.
- You have been diagnosed with HAE.
- You have access to at least 1 acute medication to treat HAE attacks.

Other requirements will apply.

**For more information about the Oasis study, contact: 844-501-0233**

## What can participants of the Oasis study expect?

- The study will last up to 46 weeks (a little less than a year).
- Participants will be randomly assigned to receive an injection of the study drug or placebo every 4 or 8 weeks.
- Participants will attend up to 11 study clinic visits (about 1 every 4 weeks) to receive study health assessments and be monitored by the study healthcare team.
- Study-related health assessments will be provided at no cost. Participants will be reimbursed for costs associated with study visits (e.g., mileage, parking).

